Cardiovascular disease in diabetes, beyond glucose
RH Eckel, KE Bornfeldt, IJ Goldberg - Cell metabolism, 2021 - cell.com
Despite the decades-old knowledge that diabetes mellitus is a major risk factor for
cardiovascular disease, the reasons for this association are only partially understood. While …
cardiovascular disease, the reasons for this association are only partially understood. While …
Metformin, macrophage dysfunction and atherosclerosis
Metformin is one of the most widely prescribed hypoglycemic drugs and has the potential to
treat many diseases. More and more evidence shows that metformin can regulate the …
treat many diseases. More and more evidence shows that metformin can regulate the …
How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial
SE Inzucchi, B Zinman, D Fitchett, C Wanner… - Diabetes …, 2018 - Am Diabetes Assoc
OBJECTIVE In the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2
Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial involving 7,020 patients with type 2 …
Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial involving 7,020 patients with type 2 …
The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials
DSH Lin, JK Lee, CS Hung, WJ Chen - Diabetologia, 2021 - Springer
Aims/hypothesis Several cardiovascular outcome trials on sodium–glucose cotransporter 2
inhibitors (SGLT2i) have been released recently, including trials enrolling patients with …
inhibitors (SGLT2i) have been released recently, including trials enrolling patients with …
Clinical adverse events associated with sodium–glucose cotransporter 2 inhibitors: a meta-analysis involving 10 randomized clinical trials and 71 553 individuals
DSH Lin, JK Lee, WJ Chen - The Journal of Clinical …, 2021 - academic.oup.com
Context SGLT2is are first-line antidiabetic agents with demonstrated cardiovascular benefits.
Prior meta-analyses have examined adverse events (AEs) associated with these drugs in …
Prior meta-analyses have examined adverse events (AEs) associated with these drugs in …
Efficacy of metformin targets on cardiometabolic health in the general population and non-diabetic individuals: a Mendelian randomization study
Background Metformin shows beneficial effects on cardiometabolic health in diabetic
individuals. However, the beneficial effects in the general population, especially in non …
individuals. However, the beneficial effects in the general population, especially in non …
Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors
DSH Lin, JK Lee, WJ Chen - Diabetologia, 2021 - Springer
Aims/hypothesis The safety and efficacy of glucagon-like peptide-1 receptor agonists
(GLP1RAs) and dipeptidyl peptidase-4 inhibitors (DPP4is) in major cardiovascular adverse …
(GLP1RAs) and dipeptidyl peptidase-4 inhibitors (DPP4is) in major cardiovascular adverse …
Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon …
CEM De Block, E Dirinck, A Verhaegen… - Diabetes, Obesity …, 2022 - Wiley Online Library
Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have become agents of choice for
people with type 2 diabetes (T2D) with established cardiovascular disease or in high‐risk …
people with type 2 diabetes (T2D) with established cardiovascular disease or in high‐risk …
Outcomes of participants with diabetes in the ISCHEMIA trials
Background: Among patients with diabetes and chronic coronary disease, it is unclear if
invasive management improves outcomes when added to medical therapy. Methods: The …
invasive management improves outcomes when added to medical therapy. Methods: The …
Anti-inflammatory therapy of atherosclerosis: focusing on IKKβ
J Gan, L Guo, X Zhang, Q Yu, Q Yang, Y Zhang… - Journal of …, 2023 - Springer
Chronic low-grade inflammation has been identified as a major contributor in the
development of atherosclerosis. Nuclear Factor-κappa B (NF-κB) is a critical transcription …
development of atherosclerosis. Nuclear Factor-κappa B (NF-κB) is a critical transcription …